Damora Therapeutics, Inc. (DMRA) Stock Price & Analysis
Damora Therapeutics, Inc. (DMRA) closed at USD 21.61 on Wednesday, October 28, 2026, down 1.59% on the day. The US market is currently closed; this is not a live price.
The prior close was USD 21.96; the Oct 28, 2026 session ranged USD 20.46–22.51 on volume of 341,763 shares. Market capitalization is $1.33B, with a 52-week range of USD 4.95–38.33 (NCM). Source: Nexqual, retrieved October 29, 2026 at 07:22 UTC.
Also available as compact Markdown for AI agents: nexqual.com/DMRA.md
Key facts (DMRA)
- 1 of 80 tracked superinvestors hold DMRA (13F, Q2 2026): 0 new, 0 added, 0 reduced, 1 unchanged.
- Insider open-market sales, last ~7 months: 1 Form 4 filings, $7K; 1 not under a Rule 10b5-1 plan ($7K); 0 by opportunistic insiders, 0 by routine insiders (three-year test, Cohen, Malloy & Pomorski 2012).
- Insider open-market purchases, last ~7 months: 1 Form 4 filing, $253K; 0 by opportunistic insiders, 0 by routine insiders.
- Analysts: Buy (mean 1.90 on a 1–5 scale) (10 analysts), mean target USD 46.89 (range 40–60).
- Total return with dividends: 1Y +189.3% vs S&P 500 +13.6%; 5Y -73.8% vs S&P 500 +79.8%.
- Next earnings: 2026-11-05, EPS estimate USD -0.44, revenue estimate $0K.
Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (DMRA)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Operating income | -$52.2M | -$61.2M | -$39.9M | -$22.3M | -$211M | -$271M |
| Net income | -$51.8M | -$61.6M | -$38.3M | -$21.4M | -$210M | -$263M |
| EPS (diluted) | -$51.25 | -$60.75 | -$36.08 | -$18.53 | $3.98 | — |
| Free cash flow | -$52.5M | -$43.1M | — | — | — | — |
| Cash + short-term investments | $100M | $60.2M | $33.2M | — | — | — |
Fiscal years end Dec. EPS is split-adjusted.
Valuation (price ÷ last four quarters, through Jun 30, 2026) (DMRA)
P/B 2.6x · Earnings yield -19.70%
Superinvestors (SEC 13F-HR, Q2 2026) (DMRA)
1 of 80 tracked investors hold DMRA. Each row is the investor's latest 13F; change is vs their prior-quarter share count.
| Investor | Firm | % of portfolio | Value | Change |
|---|---|---|---|---|
| Viking Global | Viking Global Investors | 0.17% | $60.1M | Unchanged |
Insider sales (SEC Form 4, open-market, last ~7 months) (DMRA)
0 of 1 under a Rule 10b5-1 trading plan (scheduled in advance). Unplanned sales were timed by the insider.
| Trade date | Insider | Role | Shares | Value | % of holdings sold | 10b5-1 plan | Insider type |
|---|---|---|---|---|---|---|---|
| 2026-07-06 | Winslow Garrett | General Counsel | 245 | $7K | 9.7% | No | Too little history (no open-market trades in 2023 or 2024) |
% of holdings sold = shares sold ÷ (shares sold + all holdings the insider reported on that Form 4, direct and through trusts).
Insider type follows Cohen, Malloy & Pomorski (Journal of Finance, 2012). An insider who traded the stock in the same calendar month in each of the past three years is a routine trader; one who traded in each of those years without such a pattern is an opportunistic trader. In their study, trades by opportunistic insiders predicted future returns and trades by routine insiders did not. Counts open-market purchases and sales only (SEC Form 4 codes P and S) by that insider in that company. Not investment advice.
Insider purchases (SEC Form 4, open-market, last ~7 months) (DMRA)
1 purchase, $253K. Private placements, offerings, dividend reinvestment and employee stock purchase plan buys are excluded.
| Trade date | Insider | Role | Shares | Value | Avg price | Insider type |
|---|---|---|---|---|---|---|
| 2026-09-25 | Jarrett Jennifer | Director, President and CEO | 12,500 | $253K | 20.23 | Too little history (no open-market trades in 2023–2025) |
Analysts (DMRA)
Consensus Buy (mean 1.90 on a 1–5 scale), 10 analysts; mean target USD 46.89 (low 40, high 60).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-09-29 | Wedbush | Reiterated | Outperform | $40 |
| 2026-09-25 | Guggenheim | Target raised | Buy | $40 → $60 |
| 2026-07-30 | Wedbush | Target raised | Outperform | $35 → $40 |
| 2026-07-27 | Jefferies | Initiated | Buy | $50 |
| 2026-07-21 | HC Wainwright & Co. | Reiterated | Buy | $45 |
Total return (dividends reinvested) (DMRA)
| 1Y (from 2025-10-29) | 5Y (from 2021-10-25) | |
|---|---|---|
| Total return | +189.3% | -73.8% |
| S&P 500 (SPY) | +13.6% | +79.8% |
| Per year | +190.3% | -23.5% |
| Volatility (annualized) | 163.1% | 148.9% |
| Max drawdown | -46.9% (Dec 2025→Mar 2026) | -97.4% (Nov 2021→Apr 2025) |
DMRA earnings history and stock reaction
| Results filed | Quarter | EPS | Consensus | Surprise | Stock reaction |
|---|---|---|---|---|---|
| — | Quarter ended Jun 30, 2026 | −$0.39 | −$0.37 | Miss −5.4% | — |
| — | Quarter ended Sep 30, 2025 | −$2.36 | — | — | — |
EPS as reported against the analyst consensus before the release; surprise uses the cent-rounded figures shown (in dollars when EPS and consensus have opposite signs). Stock reaction = close before the results to close after (the first close following a release after the bell or before the open).
DMRA recent SEC filings (last 120 days)
| Filed | Form | What it says |
|---|---|---|
| Aug 10, 2026 | 10-Q | Quarterly report · period ended Jun 30, 2026 |
| Jul 28, 2026 | Schedule 13G | BlackRock, Inc.: 5.1% of shares, passive 5%+ holder |
| Jul 20, 2026 | 8-K | Entered a material agreement; Change to shareholder rights; Bylaws or fiscal-year change; Regulation FD disclosure “On July 16, 2026, Damora Therapeutics, Inc., a Cayman Islands exempted company (the " Company "), entered into indemnification agreements with each of its directors and executive officers (collectively, the " Indemnitees " and, the " Indemnification Agreements "), which replaced and superseded any previous indemnification agreements between the Company and each such individual. The Indemnification Agreements provide for certain indemnification and advancement of expenses by the Company in connection with actions…” |
Source: SEC EDGAR. Quotes are the opening words of each item as filed; each form links to the filing. Insider Form 4 filings are listed in the insider sections.
DMRA suppliers, customers and competitors (named in its 10-K)
| Relationship | Company | Sentence in the filing |
|---|---|---|
| Partner | Paragon Therapeutics | “From time to time, we may choose to add additional targets to the Paragon Option Agreement by mutual agreement with Paragon and Paramora.” |
| Partner | Paramora Holding | “From time to time, we may choose to add additional targets to the Paragon Option Agreement by mutual agreement with Paragon and Paramora.” |
| Partner | WuXi | “Furthermore, if one or more of our collaborators or vendors in China, including WuXi Biologics (Hong Kong), is named a biotechnology company of concern, our operations and financial condition may be negatively impacted as a result of any delays or increased costs arising from the trade restrictions and other foreign regulatory requirements affecting such collaborators.” |
| Partner | Bridge Medicines | “Cash used in operating activities of $18.6 million during the year ended December 31, 2024 was attributable to our net loss of $21.4 million and a net decrease of $2.7 million in our working capital, offset by a net increase in non-cash items of $5.5 million principally with respect to non-cash stock-based compensation, non-cash issuance of common stock and preferred stock in connection with the asset purchase agr…” |
| Related party | Fairmount Funds Management | “We consider Paragon, Paramora, and Fairmount to be related parties.” |
Quoted from the company's 10-K filed Mar 19, 2026.
DMRA analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends Sep 2026) | $-0.43 | $-0.40 | −$0.04 | $0 | 4 |
| Next quarter (ends Dec 2026) | $-0.47 | $-0.43 | −$0.04 | $0 | 4 |
| Current fiscal year (ends Dec 2026) | $-1.90 | $-1.75 | −$0.14 | $0 | 4 |
| Next fiscal year (ends Dec 2027) | $-2.17 | $-2.08 | −$0.09 | $0 | 4 |
Key Statistics (as of October 29, 2026 at 07:22 UTC)
| Price | USD 21.61 |
|---|---|
| Change | ▼ 1.59% (down) |
| Previous Close | USD 21.96 |
| Open | USD 21.93 |
| Day Range | USD 20.46 – 22.51 |
| 52-Week Range | USD 4.95 – 38.33 |
| Volume | 341,763 shares |
| Market Cap | $1.33B |
| Exchange | NCM |
Technical Analysis (DMRA)
Nexqual's technical model rates DMRA "NEUTRAL" based on 2 bullish and 3 bearish signals across 127 daily candles, as of October 29, 2026 at 07:22 UTC.
| Overall Signal | NEUTRAL |
|---|---|
| RSI (14) | 46.14 (neutral) |
| vs SMA50 | Below (USD 23.92) |
| MACD | -0.49 (negative) |
Analyst Ratings (DMRA)
Wall Street analysts rate DMRA "Buy" based on 10 analysts, with a mean price target of USD 46.89 (range USD 40–60), per Nexqual as of October 29, 2026 at 07:22 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 10 |
| Mean Target | USD 46.89 |
| High Target | USD 60 |
| Low Target | USD 40 |
| Buy / Hold / Sell | 10 / 0 / 0 |
Earnings (DMRA)
| Next Earnings Date | 2026-11-05 |
|---|---|
| EPS Estimate | USD -0.44 |
| Revenue Estimate | $0 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD -0.39 vs est -0.37 ▼ miss |
Source: Nexqual, October 29, 2026 at 07:22 UTC.
Financials & Fundamentals (DMRA)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | -99.74% |
| Current Ratio | 19.73 |
| Total Cash | $540.52M |
| Total Debt | $0 |
Source: Nexqual, October 29, 2026 at 07:22 UTC.
Financial Health Score (DMRA)
Nexqual rates Damora Therapeutics, Inc.'s overall financial health "Weak" across five dimensions, as of October 29, 2026 at 07:22 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Mixed — $541M cash, no debt |
| Cash Flow | Weak — Operating cash flow -$7M (FY ended Dec 2025, 10-K) |
| Efficiency | Critical — ROE -51%, ROA -48.3% (last 4 quarters, SEC) |
Ownership (DMRA)
| Insider Ownership | +8.43% |
|---|---|
| Institutional Ownership | +105.83% |
| Shares Outstanding | 61.74M |
| Float | 40.89M |
| Short % of Float | +9.74% |
Source: Nexqual, October 29, 2026 at 07:22 UTC.
Leadership (DMRA)
Damora Therapeutics, Inc. is led by Jennifer A. Jarrett, CEO, President & Director, per Nexqual as of October 29, 2026 at 07:22 UTC.
| CEO, President & Director | Jennifer A. Jarrett |
|---|---|
| Chief Operating Officer | Sherwin Sattarzadeh |
Major Backers & Investors (DMRA)
Notable institutional backers of Damora Therapeutics, Inc. include Fidelity, according to Nexqual as of October 29, 2026 at 07:22 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Fidelity | 9.1% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 1.99% |
| State Street | 1.17% |
Source: Nexqual, October 29, 2026 at 07:22 UTC.
From Damora Therapeutics, Inc.'s Latest SEC 10-K Filing (filed 2026-03-19)
Key Strengths & Strategy (as disclosed to the SEC)
- We seek to protect our proprietary information, in part by executing confidentiality agreements with our collaborators and scientific advisors, and non-competition, non-solicitation, confidentiality and invention assignment agreements with our employees and consultants.
- The confidentiality agreements we enter into are designed to protect our proprietary information and the agreements or clauses requiring assignment of inventions to us are designed to grant us ownership of technologies that are developed through our relationship with the respective counterparty.
- Should any of our product candidates be approved for commercialization, we intend to develop a plan to commercialize them in the United States and other key markets, through internal infrastructure and/or external partnerships in a manner that will enable us to realize the full commercial value of our programs.
- Our manufacturing strategy enables us to more efficiently direct financial resources to the research, development and commercialization of programs rather than diverting resources to internally develop and maintain manufacturing facilities.
Partnerships
- Under the Paragon Option Agreement, we have an option (an "Option"), on a Research Program-by-Research Program basis, to enter into a separate agreement with Paragon consistent with a set of pre-negotiated terms (a "License Agreement").
- On February 10, 2026, we also entered into an underwriting agreement with certain underwriters to issue and sell 14,473,685 shares of our common stock, including the full exercise by the underwriters of their option to purchase an additional 2,171,052 shares, at a public offering price of $19.00 per share.
Legal & Regulatory Risks (Item 1A, quoted)
- We may not be able to meet requirements for the chemistry, manufacturing and control of our product candidates.
- Our product candidates for which we intend to seek approval as biologics may face competition from biosimilars sooner than anticipated.
- We may face difficulties from healthcare and regulatory legislative reform measures.
- Our business operations and current and future arrangements with investigators, healthcare professionals, consultants, third-party payors, patient organizations and customers will be subject to applicable healthcare regulatory laws, which could expose us to penalties.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| ORKA | Oruka Therapeutics, Inc. | USD 95.97 | ▲ 0.17% |
| LGND | Ligand Pharmaceuticals Incorpor | USD 318.78 | ▲ 2.26% |
| IOVA | Iovance Biotherapeutics, Inc. | USD 14.81 | ▲ 1.58% |
| IONS | Ionis Pharmaceuticals, Inc. | USD 44.9 | ▲ 2.14% |
| AXSM | Axsome Therapeutics, Inc. | USD 143.51 | ▲ 0.92% |
| ABVX | Abivax SA | USD 89.84 | ▲ 3.26% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 29, 2026 at 07:22 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt